Results 211 to 220 of about 206,427 (382)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Efficacy of paracetamol added to WHO step III opioids in chronic pain control: study protocol for a randomised, double-blind, placebo-controlled, non-inferiority, multicentre study in Switzerland. [PDF]

BMJ Open
Kotoula C, Wertli MM, Streitberger K, Rothschild SI, Limacher A, Hammann F, Krähenbühl S, Haschke M, Liakoni E.   +8 more
europepmc   +1 more source

Development of a UV-spectrophotometric method for the simultaneous determination of aspirin and paracetamol in tablets

, 2011
G. Murtaza, Izhar Hussain, Shujaat Ali Khan, Arham Shabbir, Arshad Mahmood, Muhammad Hassham Hassan Bin Asad, Kalsoom Farzanal, Nadia Shamshad Malik   +7 more
openalex   +2 more sources

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Randomized open-label non-inferiority trial of paracetamol or celecoxib for patients with chronic low back pain. [PDF]

Sci Rep
Hayashi K, Miki K, Ueno H, Sekiguchi M, Arai YC, Nikaido T, Shiga Y, Inoue M, Kataoka H, Kawarai Y, Kimura Y, Shimizu K, Shimo K, Shiro Y, Tanaka K, Tanaka S, Hirakawa Y, Miura K, Yukioka M.   +18 more
europepmc   +1 more source

Parental calculation of pediatric paracetamol dose: a randomized trial comparing the Parental Analgesia Slide with product information leaflets

, 2010
RICHARD HIXSON, Uwe Franke, Rohit Mittal, Mika Hamilton   +3 more
openalex   +2 more sources

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Cost-Effectiveness of Metoclopramide, Paracetamol, and Ceftriaxone for the Prevention of Infections and Fever in Elderly Patients with Acute Stroke. [PDF]

MDM Policy Pract
Vervaart M, de Jonge JC, Bath PM, Melberg HO, Reinink H, Sluis WM, Woodhouse LJ, van der Worp HB, Aamodt AH, PRECIOUS Investigators.   +9 more
europepmc   +1 more source

Hepatoprotective and antioxidant activity of Murraya Koenigii leaves extract against paracetamol induced hepatotoxicity in Rats

, 2017
Kartik Janardan Salwe, R Mirunalini, Jervin Mano, K. Manimekalai   +3 more
openalex   +2 more sources

Paracetamol Hepatotoxicity [PDF]

Journal of the Royal Society of Medicine, 1997
openaire   +2 more sources